LENSAR (NASDAQ:LNSR) Earns Hold Rating from Lake Street Capital

Lake Street Capital reiterated their hold rating on shares of LENSAR (NASDAQ:LNSR) in a report published on Monday morning, Marketbeat.com reports. They currently have a $15.00 price objective on the stock, down from their previous price objective of $16.00.

LENSAR Stock Down 0.2 %

Shares of NASDAQ:LNSR opened at $14.14 on Monday. LENSAR has a 52-week low of $2.67 and a 52-week high of $17.31. The stock has a market cap of $166.70 million, a price-to-earnings ratio of -9.68 and a beta of 0.62. The business has a 50-day moving average price of $11.81 and a 200-day moving average price of $8.36.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%. The business had revenue of $16.73 million during the quarter, compared to analyst estimates of $14.95 million.

Institutional Investors Weigh In On LENSAR

Several hedge funds have recently added to or reduced their stakes in LNSR. Geode Capital Management LLC raised its stake in shares of LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after buying an additional 3,423 shares during the last quarter. Evernest Financial Advisors LLC acquired a new stake in LENSAR during the fourth quarter worth about $174,000. Bailard Inc. acquired a new stake in LENSAR during the fourth quarter worth about $181,000. Atria Investments Inc raised its position in LENSAR by 28.2% during the fourth quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after acquiring an additional 5,729 shares in the last quarter. Finally, Essex Investment Management Co. LLC lifted its holdings in LENSAR by 18.3% in the fourth quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock valued at $357,000 after acquiring an additional 6,184 shares during the period. 40.15% of the stock is owned by hedge funds and other institutional investors.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.